Sign In
Buy ZURA
$4.31
+0.0750 (+1.77%)
At Close: Jun 23, 2026
Zura Bio Announces Participation in June Investor Conferences
06:00am, Wednesday, 29'th May 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and
3 Penny Stocks to Buy Now: May 2024
06:18am, Friday, 24'th May 2024
Penny stocks to buy carry a considerable amount of risk. That's why we include the disclaimer at the tail-end of this article.
How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%
10:55am, Wednesday, 15'th May 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Zura Bio Limited (ZURA). While the effectiveness of this highly sought-after metric is questionable,
Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should Know
01:01pm, Tuesday, 14'th May 2024
Zura Bio Limited (ZURA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
These Biotechs and IPOs Inspire Big Insider Buying
08:15am, Sunday, 28'th Apr 2024
As tech giants and other sector leaders report their most recent quarterly results, one might expect notable insider purchases to be scarce.
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
09:22am, Thursday, 18'th Apr 2024
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflamm
Zura Bio Announces Robert Lisicki as CEO and Director
06:00am, Monday, 08'th Apr 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and i
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
06:00am, Thursday, 28'th Mar 2024
HENDERSON, Nev--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and in
Zura Bio Announces Participation at March Conferences
06:00am, Monday, 04'th Mar 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio announces participation at three March conferences.
Zura Bio Announces Participation at February Investor Conferences
06:00am, Friday, 02'nd Feb 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio today announced participation at several upcoming conferences in February.
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
06:00am, Monday, 08'th Jan 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Announces Appointment of Robert Lisicki as President and Dr. Kiran Nistala as CMO.
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit
06:00am, Wednesday, 03'rd Jan 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit.
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok
06:00am, Monday, 04'th Dec 2023
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio announces two immunology abstracts presented at World Allergy Congress (WAC) for ZB-168 and ZB-880.
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors
06:00am, Tuesday, 14'th Nov 2023
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) announced Arnout Ploos van Amstel has been appointed to its Board of Directors.
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
06:30am, Monday, 13'th Nov 2023
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immu
